TAS2R20

Summary

TAS2R20 (taste 2 receptor member 20, HGNC:19109) is a protein-coding gene on chromosome 12p13.2, encoding Taste receptor type 2 member 20 (P59543). Receptor that may play a role in the perception of bitterness and is gustducin-linked.

This gene encodes a member of the taste receptor two family of class C G-protein coupled receptors. Receptors of this family have a short extracellular N-terminus, seven transmembrane helices, three extracellular loops and three intracellular loops, and an intracellular C-terminus. Members of this family are expressed in a subset of taste receptor cells, where they function in bitter taste reception, as well as in non-gustatory cells including those of the brain, reproductive organs, respiratory system, and gastrointestinal system. This gene maps to the taste receptor gene cluster on chromosome 12p13.

Source: NCBI Gene 259295 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 1 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_176889

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19109
Approved symbol	TAS2R20
Name	taste 2 receptor member 20
Location	12p13.2
Locus type	gene with protein product
Status	Approved
Aliases	T2R20, T2R56
Ensembl gene	ENSG00000255837
Ensembl biotype	protein_coding
OMIM	613962
Entrez	259295

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000538986

RefSeq mRNA: 1 — MANE Select: NM_176889 NM_176889

CCDS: CCDS8639

Canonical transcript exons

ENST00000538986 — 1 exons

Exon	Start	End
ENSE00001727283	10995961	10998304

Expression profiles

Bgee: expression breadth ubiquitous, 129 present calls, max score 73.98.

Top tissues by expression

132 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
corpus callosum	UBERON:0002336	73.98	gold quality
calcaneal tendon	UBERON:0003701	71.32	gold quality
adrenal tissue	UBERON:0018303	70.94	gold quality
right ovary	UBERON:0002118	68.73	gold quality
left ovary	UBERON:0002119	68.19	gold quality
tibial nerve	UBERON:0001323	68.03	gold quality
skeletal muscle tissue	UBERON:0001134	67.77	gold quality
endometrium	UBERON:0001295	67.61	gold quality
gastrocnemius	UBERON:0001388	67.47	gold quality
muscle of leg	UBERON:0001383	67.41	gold quality
body of uterus	UBERON:0009853	67.38	gold quality
ovary	UBERON:0000992	67.20	gold quality
stromal cell of endometrium	CL:0002255	66.61	gold quality
myometrium	UBERON:0001296	65.95	gold quality
subcutaneous adipose tissue	UBERON:0002190	65.81	gold quality
spleen	UBERON:0002106	64.44	gold quality
right lobe of thyroid gland	UBERON:0001119	64.38	gold quality
hindlimb stylopod muscle	UBERON:0004252	64.06	gold quality
thoracic mammary gland	UBERON:0005200	64.03	gold quality
right uterine tube	UBERON:0001302	63.96	gold quality
left lobe of thyroid gland	UBERON:0001120	63.92	gold quality
ectocervix	UBERON:0012249	63.89	gold quality
thyroid gland	UBERON:0002046	63.82	gold quality
right adrenal gland	UBERON:0001233	63.72	gold quality
right adrenal gland cortex	UBERON:0035827	63.72	gold quality
muscle layer of sigmoid colon	UBERON:0035805	63.71	gold quality
adipose tissue	UBERON:0001013	63.61	gold quality
endocervix	UBERON:0000458	63.57	gold quality
popliteal artery	UBERON:0002250	63.52	gold quality
tibial artery	UBERON:0007610	63.52	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

45 targeting TAS2R20, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-4648	99.91	67.00	710
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-548M	99.70	68.87	1749
HSA-MIR-567	99.63	68.57	1219
HSA-MIR-2113	99.58	71.22	1521
HSA-MIR-4452	99.50	68.45	1493
HSA-MIR-4643	99.49	67.63	1791
HSA-MIR-6083	99.47	68.73	2393
HSA-MIR-4762-3P	99.43	69.72	2363
HSA-MIR-372-5P	99.41	69.11	2299
HSA-MIR-183-3P	99.41	69.41	1598
HSA-MIR-4251	99.40	69.19	3363

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Tas2r136	ENSMUSG00000053217
mus_musculus	Tas2r120	ENSMUSG00000059382
rattus_norvegicus	Tas2r120	ENSRNOG00000021445
rattus_norvegicus	Tas2r136	ENSRNOG00000029561

Paralogs (23): TAS2R8 (ENSG00000121314), TAS2R10 (ENSG00000121318), TAS2R7 (ENSG00000121377), TAS2R9 (ENSG00000121381), TAS2R3 (ENSG00000127362), TAS2R4 (ENSG00000127364), TAS2R5 (ENSG00000127366), TAS2R16 (ENSG00000128519), TAS2R1 (ENSG00000169777), TAS2R60 (ENSG00000185899), TAS2R42 (ENSG00000186136), TAS2R19 (ENSG00000212124), TAS2R50 (ENSG00000212126), TAS2R14 (ENSG00000212127), TAS2R13 (ENSG00000212128), TAS2R41 (ENSG00000221855), TAS2R40 (ENSG00000221937), TAS2R46 (ENSG00000226761), TAS2R39 (ENSG00000236398), TAS2R43 (ENSG00000255374), TAS2R30 (ENSG00000256188), TAS2R31 (ENSG00000256436), TAS2R38 (ENSG00000257138)

Protein

Protein identifiers

Taste receptor type 2 member 20 — P59543 (reviewed: P59543)

Alternative names: Taste receptor type 2 member 49, Taste receptor type 2 member 56

All UniProt accessions (1): P59543

UniProt curated annotations — full annotation on UniProt →

Function. Receptor that may play a role in the perception of bitterness and is gustducin-linked. May play a role in sensing the chemical composition of the gastrointestinal content. The activity of this receptor may stimulate alpha gustducin, mediate PLC-beta-2 activation and lead to the gating of TRPM5.

Subcellular location. Membrane.

Tissue specificity. Expressed in subsets of taste receptor cells of the tongue and exclusively in gustducin-positive cells.

Miscellaneous. Most taste cells may be activated by a limited number of bitter compounds; individual taste cells can discriminate among bitter stimuli.

Similarity. Belongs to the G-protein coupled receptor T2R family.

RefSeq proteins (1): NP_795370* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007960	TAS2R	Family

Pfam: PF05296

UniProt features (27 total): topological domain 8, transmembrane region 7, sequence variant 6, sequence conflict 3, glycosylation site 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P59543-F1	87.17	0.50

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 161, 176

Function

Pathways and Gene Ontology

Reactome pathways

9 pathways

ID	Pathway
R-HSA-418594	G alpha (i) signalling events
R-HSA-420499	Class C/3 (Metabotropic glutamate/pheromone receptors)
R-HSA-9717207	Sensory perception of sweet, bitter, and umami (glutamate) taste
R-HSA-162582	Signal Transduction
R-HSA-372790	Signaling by GPCR
R-HSA-388396	GPCR downstream signalling
R-HSA-500792	GPCR ligand binding
R-HSA-9709957	Sensory Perception
R-HSA-9717189	Sensory perception of taste

MSigDB gene sets: 32 (showing top): GOBP_SENSORY_PERCEPTION_OF_CHEMICAL_STIMULUS, GOBP_DETECTION_OF_CHEMICAL_STIMULUS_INVOLVED_IN_SENSORY_PERCEPTION_OF_TASTE, GOBP_SENSORY_PERCEPTION_OF_TASTE, GOBP_DETECTION_OF_STIMULUS, GOBP_SENSORY_PERCEPTION, GOMF_TRANSMEMBRANE_SIGNALING_RECEPTOR_ACTIVITY, GOMF_BITTER_TASTE_RECEPTOR_ACTIVITY, GOMF_TASTE_RECEPTOR_ACTIVITY, GOMF_G_PROTEIN_COUPLED_RECEPTOR_ACTIVITY, GOBP_G_PROTEIN_COUPLED_RECEPTOR_SIGNALING_PATHWAY, GOBP_DETECTION_OF_STIMULUS_INVOLVED_IN_SENSORY_PERCEPTION, GOBP_SENSORY_PERCEPTION_OF_BITTER_TASTE, MIR616_5P, MIR371B_5P, MIR373_5P

GO Biological Process (4): detection of chemical stimulus involved in sensory perception of bitter taste (GO:0001580), signal transduction (GO:0007165), G protein-coupled receptor signaling pathway (GO:0007186), sensory perception of taste (GO:0050909)

GO Molecular Function (2): G protein-coupled receptor activity (GO:0004930), bitter taste receptor activity (GO:0033038)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Signaling by GPCR	2
GPCR downstream signalling	1
GPCR ligand binding	1
Sensory perception of taste	1
Signal Transduction	1
Sensory Perception	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
detection of chemical stimulus involved in sensory perception of taste	1
sensory perception of bitter taste	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
G protein-coupled receptor activity	1
signal transduction	1
sensory perception of chemical stimulus	1
transmembrane signaling receptor activity	1
G protein-coupled receptor signaling pathway	1
detection of chemical stimulus involved in sensory perception of bitter taste	1
taste receptor activity	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

278 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TAS2R20	RTP3	Q9BQQ7	567
TAS2R20	TAS2R1	Q9NYW7	532
TAS2R20	SSTR3	P32745	427
TAS2R20	TAS1R2	Q8TE23	412
TAS2R20	TAS1R3	Q7RTX0	398
TAS2R20	TAS1R1	Q7RTX1	380
TAS2R20	KRTAP24-1	Q3LI83	378
TAS2R20	SIL1	Q9H173	372
TAS2R20	SLC23A1	Q9UHI7	369
TAS2R20	KIAA1328	Q86T90	368
TAS2R20	VN1R1	Q9GZP7	359
TAS2R20	OR1E2	P47887	353
TAS2R20	OR1E1	P30953	353
TAS2R20	OR1B1	Q8NGR6	353
TAS2R20	TRIOBP	Q9H2D6	353
TAS2R20	TMCO1	Q9UM00	353

IntAct

2 interactions, top by confidence:

A	B	Type	Score
TAS2R20	PRKCA	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (1): PRKCA (Affinity Capture-MS)

ESM2 similar proteins: P0DSN6, P0DTE0, P59537, P59538, P59539, P59540, P59541, P59542, P59543, P59544, Q5Y4Y8, Q5Y4Y9, Q5Y4Z5, Q5Y4Z8, Q5Y500, Q645T2, Q645T3, Q645T4, Q645T6, Q645V2, Q645V3, Q645V4, Q645V6, Q645V7, Q645Z2, Q645Z6, Q645Z7, Q645Z9, Q646A0, Q646A1, Q646B4, Q646B9, Q646C0, Q646C1, Q646C2, Q646C3, Q646E0, Q646E1, Q646E2, Q646E3

Diamond homologs: P0DSN6, P0DTE0, P59528, P59530, P59537, P59538, P59539, P59540, P59541, P59542, P59543, P59544, Q5Y4Y8, Q5Y4Y9, Q5Y4Z5, Q5Y4Z8, Q5Y500, Q645T0, Q645T2, Q645T3, Q645T4, Q645T6, Q645T7, Q645U8, Q645V1, Q645V2, Q645V3, Q645V4, Q645V6, Q645V7, Q645V8, Q645V9, Q645Z2, Q645Z5, Q645Z6, Q645Z7, Q645Z9, Q646A0, Q646A1, Q646A2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

1 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	1
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

293 predictions. Top by Δscore:

Variant	Effect	Δscore
12:10997456:C:CT	acceptor_gain	0.8900
12:10997457:A:T	acceptor_gain	0.8500
12:10997836:CTA:C	acceptor_gain	0.8500
12:10997261:A:C	acceptor_gain	0.8100
12:10997265:T:TC	acceptor_gain	0.8000
12:10997268:C:CT	acceptor_gain	0.8000
12:10997270:C:CT	acceptor_gain	0.7700
12:10997276:G:GC	acceptor_gain	0.7700
12:10997691:A:AC	donor_gain	0.7700
12:10997281:T:TC	acceptor_gain	0.7600
12:10997118:T:C	acceptor_gain	0.7200
12:10997276:G:C	acceptor_gain	0.6900
12:10996247:TGA:T	donor_gain	0.6800
12:10997118:T:TG	acceptor_gain	0.6800
12:10997271:A:T	acceptor_gain	0.6700
12:10997286:A:T	acceptor_gain	0.6700
12:10997288:C:CT	acceptor_gain	0.6700
12:10997261:A:AC	acceptor_gain	0.6400
12:10997265:T:C	acceptor_gain	0.6400
12:10997289:A:T	acceptor_gain	0.6200
12:10997119:T:G	acceptor_gain	0.6000
12:10996998:ACTG:A	acceptor_gain	0.5900
12:10997839:C:CC	acceptor_gain	0.5900
12:10997258:CAGA:C	acceptor_gain	0.5800
12:10997710:CT:C	donor_gain	0.5800
12:10997000:T:A	acceptor_gain	0.5700
12:10997619:T:TC	acceptor_gain	0.5700
12:10997838:A:AC	acceptor_gain	0.5700
12:10996997:AACT:A	acceptor_gain	0.5600
12:10997441:C:CT	acceptor_gain	0.5600

AlphaMissense

2028 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:10997591:G:C	S95R	0.892
12:10997591:G:T	S95R	0.892
12:10997593:T:G	S95R	0.892
12:10997174:G:C	F234L	0.884
12:10997174:G:T	F234L	0.884
12:10997176:A:G	F234L	0.884
12:10997798:A:C	F26L	0.858
12:10997798:A:T	F26L	0.858
12:10997800:A:G	F26L	0.858
12:10997567:G:C	S103R	0.835
12:10997567:G:T	S103R	0.835
12:10997569:T:G	S103R	0.835
12:10997825:A:C	F17L	0.831
12:10997825:A:T	F17L	0.831
12:10997827:A:G	F17L	0.831
12:10997711:T:A	R55S	0.829
12:10997711:T:G	R55S	0.829
12:10997573:G:C	S101R	0.822
12:10997573:G:T	S101R	0.822
12:10997575:T:G	S101R	0.822
12:10997698:A:G	W60R	0.791
12:10997698:A:T	W60R	0.791
12:10997804:A:C	N24K	0.787
12:10997804:A:T	N24K	0.787
12:10997818:C:G	G20R	0.785
12:10997818:C:T	G20R	0.785
12:10997522:A:C	F118L	0.751
12:10997522:A:T	F118L	0.751
12:10997524:A:G	F118L	0.751
12:10997312:G:C	F188L	0.748

dbSNP variants (sampled 300 via entrez): RS1000641588 (12:10996167 A>C), RS1000946678 (12:10999139 T>C), RS1001231818 (12:10996771 T>A), RS1002575526 (12:10998282 G>A,T), RS1002903644 (12:10995642 T>C), RS1004085569 (12:10998345 G>A), RS1004135711 (12:10998149 T>A), RS1004686219 (12:11000036 T>C), RS1005044815 (12:10999755 G>A,C), RS1005448444 (12:10996917 A>T), RS1005466069 (12:10999440 G>A), RS1007425038 (12:11000171 T>C), RS1007674736 (12:10996095 C>A), RS1007764849 (12:10996214 A>G), RS1007790569 (12:10995766 T>C)

Disease associations

OMIM: gene MIM:613962 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3559705 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 40,234 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL434	ISOPROTERENOL	4	40,234

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Taste 2 receptors

Most potent curated ligand interactions (5 total), top 5:

Ligand	Action	Affinity	Parameter
ritanserin	Agonist	5.22	pEC50
methoxsalen	Agonist	4.92	pEC50
cromoglicic acid	Agonist	4.35	pEC50
tobramycin	Agonist	4.29	pEC50
vanillin	Agonist	3.28	pEC50

ChEMBL bioactivities

1 potent at pChembl≥5 of 1 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.31	EC50	4.9	nM	ISOPROTERENOL

CTD chemical–gene interactions

10 total (human), top 10 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Aflatoxin B1	decreases methylation, decreases expression	2
GSK-J4	increases expression	1
bisphenol A	increases expression	1
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
Cadmium	increases abundance, decreases expression	1
Hydrogen Peroxide	decreases expression	1
Cadmium Chloride	decreases expression, increases abundance	1
Permethrin	increases expression	1

ChEMBL screening assays

6 unique, capped per target: 6 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4419023	Functional	Agonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R49 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as increase in intracellular calcium level at 100 uM by FLIPR assay	Methods of identifying antagonists of the hTAS2R46 bitter taste receptor

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer